B K Dunn

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Epigenetics in cancer prevention: early detection and risk assessment: introduction
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Executive Plaza North, Rockville, Maryland 20852 7362, USA
    Ann N Y Acad Sci 983:1-4. 2003
  2. doi request reprint Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities
    Barbara K Dunn
    Basic Prevention Science Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
    Recent Results Cancer Res 188:21-47. 2011
  3. pmc Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT)
    Holly L Nicastro
    Cancer Prevention Fellowship Program, Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Dr, Rockville, MD 20850, USA
    Nutrients 5:1122-48. 2013
  4. doi request reprint Biomarkers as surrogate endpoints in cancer trials
    Barbara K Dunn
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Semin Oncol Nurs 28:99-108. 2012
  5. doi request reprint Molecular markers for early detection
    Barbara K Dunn
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7340, USA
    Semin Oncol 37:224-42. 2010
  6. doi request reprint Health disparities in breast cancer: biology meets socioeconomic status
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
    Breast Cancer Res Treat 121:281-92. 2010
  7. doi request reprint A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nutr Cancer 62:896-918. 2010
  8. doi request reprint Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators
    Barbara K Dunn
    US National Cancer Institute, Division of Cancer Prevention, USA
    Ann N Y Acad Sci 1155:141-61. 2009
  9. ncbi request reprint Conclusions: Considerations regarding SERMs
    B K Dunn
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Ann N Y Acad Sci 949:352-65. 2001
  10. ncbi request reprint Hypomethylation: one side of a larger picture
    Barbara K Dunn
    Basic Prevention Sciences Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 983:28-42. 2003

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Epigenetics in cancer prevention: early detection and risk assessment: introduction
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Executive Plaza North, Rockville, Maryland 20852 7362, USA
    Ann N Y Acad Sci 983:1-4. 2003
  2. doi request reprint Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities
    Barbara K Dunn
    Basic Prevention Science Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
    Recent Results Cancer Res 188:21-47. 2011
    ....
  3. pmc Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT)
    Holly L Nicastro
    Cancer Prevention Fellowship Program, Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Dr, Rockville, MD 20850, USA
    Nutrients 5:1122-48. 2013
    ....
  4. doi request reprint Biomarkers as surrogate endpoints in cancer trials
    Barbara K Dunn
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Semin Oncol Nurs 28:99-108. 2012
    ....
  5. doi request reprint Molecular markers for early detection
    Barbara K Dunn
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7340, USA
    Semin Oncol 37:224-42. 2010
    ....
  6. doi request reprint Health disparities in breast cancer: biology meets socioeconomic status
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
    Breast Cancer Res Treat 121:281-92. 2010
    ..We will attempt to clarify some of the issues, including risk factors, in terms of their contribution to that component of health disparities that involves biological differences in breast cancer between women of AA and white women...
  7. doi request reprint A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nutr Cancer 62:896-918. 2010
    ..07, P = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men...
  8. doi request reprint Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators
    Barbara K Dunn
    US National Cancer Institute, Division of Cancer Prevention, USA
    Ann N Y Acad Sci 1155:141-61. 2009
    ..The Study of Letrozole and Raloxifene (STELLAR), using as the control raloxifene, the new U.S. standard drug for BC prevention, would complete the trio of AI prevention trials, but STELLAR is currently on hold...
  9. ncbi request reprint Conclusions: Considerations regarding SERMs
    B K Dunn
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Ann N Y Acad Sci 949:352-65. 2001
    ..Finally, we explore the process by which statistically meaningful results from clinical trials are extrapolated into the specific drug indications that apply to clinical practice...
  10. ncbi request reprint Hypomethylation: one side of a larger picture
    Barbara K Dunn
    Basic Prevention Sciences Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 983:28-42. 2003
    ..Thus, hypomethylation, in a variety of settings in which it represents a deviation from "normal," appears to correlate with progression to cancer and offers potential mechanisms to explain the carcinogenic process...
  11. doi request reprint The application of genetics and genomics to cancer prevention
    Kathleen Calzone
    Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Oncol 37:407-18. 2010
    ..Here, we provide an overview of the scope of genetic and genomic influences on cancer risk assessment and the entire spectrum of cancer prevention...
  12. pmc Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial
    Sarah J Nyante
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Rockville, MD 20852, USA
    Gynecol Oncol 120:474-9. 2011
    ..We examined relationships between histopathologic diagnoses, false-positive test group, and participant and screening test characteristics...
  13. doi request reprint Landmarks in the history of cancer epidemiology
    Peter Greenwald
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 69:2151-62. 2009
    ....
  14. ncbi request reprint Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention
    Mukesh Verma
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    Ann N Y Acad Sci 983:298-319. 2003
    ..Further research will lead to the identification of new targets for cancer prevention...
  15. ncbi request reprint Do we make optimal use of the potential of cancer prevention?
    Peter Greenwald
    National Cancer Institute NIH, Division of Cancer Prevention, Bethesda, MD 20892, USA
    Recent Results Cancer Res 181:3-17. 2009
    ..Training current researchers in new approaches will add efficiency to their combined research experiences...
  16. ncbi request reprint Opportunities for future research
    S Sherman
    National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 949:366-74. 2001
    ....
  17. doi request reprint Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer
    Tanya Agurs-Collins
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 37:384-401. 2010
    ..We will attempt to clarify some of the issues, in terms of their contribution to that component of health disparities that involves biological differences in breast cancer between women of African ancestry and white women...
  18. ncbi request reprint Prevention of hormone-related cancers: breast cancer
    Barbara K Dunn
    National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892, USA
    J Clin Oncol 23:357-67. 2005
    ....
  19. ncbi request reprint From adjuvant therapy to breast cancer prevention: BCPT and STAR
    B K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Breast J 7:144-57. 2001
    ..Study endpoints include invasive and noninvasive breast cancer, cardiovascular disease, endometrial cancer, bone fractures, and vascular events...
  20. ncbi request reprint Hormonal interventions to prevent hormonal cancers: breast and prostate cancers
    Barbara K Dunn
    Basic Prevention Science Research Group bNational Cancer Institute, Division of Cancer Prevention, Deputy Directors Office, Bethesda, Maryland 20892 7309, USA
    Eur J Cancer Prev 16:232-42. 2007
    ....
  21. pmc Influence of genetic background and tissue types on global DNA methylation patterns
    Howard H Yang
    Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9355. 2010
    ..Furthermore, we showed that tissue types are important contributors of DNA methylation states...
  22. pmc Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines
    Mitsutaka Kadota
    Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9201. 2010
    ....
  23. pmc Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA
    Mitsutaka Kadota
    Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 69:7357-65. 2009
    ..Our gene amplification and somatic mutation analysis of breast primary tumors provides a coherent picture of genetic events, both corroborating and novel, offering insight into the genetic underpinnings of breast cancer progression...